Home
Search
thewest.com.au
BusinessChevron Right Icon

Biotech

Kim Beazley joined the board of Perth biotech Orthocell last year.

BiotechCommentsPremiumHealth issues force Kim Beazley’s exit from Orthocell

Former WA governor and US ambassador Kim Beazley will step down from the board of Perth regenerative medicine company Orthocell due to health reasons.

Cheyanne Enciso

CSL is Australia’s third-biggest company by market capitalisation at over $120 billion.

BiotechCommentsTrump pharma tariff to have ‘limited’ impact on biotech: UBS

Investment bank UBS expects Donald Trump’s tariff threat on pharmaceuticals to have ‘limited’ impact on biotech giant CSL, especially if plasma products are excluded.

Cheyanne Enciso

Medicines and pharmaceutical products were the third-largest good exported to the US in 2024, with the trade worth more than $2 billion that year.

BiotechCommentsPremiumTrump’s pharma tariff could send local biotechs offshore

The peak body for Australia’s life sciences industry has flagged concerns Donald Trump’s pharmaceutical tariff threat could force more local biotechs and medical technology firms to move operations overseas.

Cheyanne Enciso

Orthocell chair John Van Der Wielen with chief executive officer Paul Anderson.

BiotechCommentsPremiumTrump’s pharma tariff threat a ‘cage-rattling exercise’

The boss of WA regenerative medicine company Orthocell has labelled Donald Trump’s latest tariff threat on pharmaceuticals as a ‘cage-rattling exercise’ to try elicit panic from the Australian Government.

Cheyanne Enciso

Orthocell chair John Van Der Wielen with chief executive officer Paul Anderson.

BiotechCommentsPremiumOrthocell shares higher as WA biotech posts record revenue

WA biotech Orthocell has posted record revenue for the June quarter as sales for its nerve repair technology surge in Australia, ahead of an expected ramp up in US.

Cheyanne Enciso

Orthocell chief executive Paul Anderson and chair John Van Der Wielen.

BiotechCommentsPremiumOrthocell’s nerve repair tech marks first surgical use in US

WA regenerative medicine firm Orthocell says it has marked another commercialisation milestone with the first successful surgical use of its nerve repair product in the US.

Cheyanne Enciso

Argenica Therapeutics boss Liz Dallimore.

BiotechCommentsPremiumWA’s Argenica wins $1m funding for life-saving stroke drug

The Federal Government is pumping $1 million into WA biotech Argenica Therapeutics to advance global clinical trials for its potentially life-saving stroke drug.

Cheyanne Enciso

Emyria executive director Michael Winlo.

BiotechCommentsPremiumEmyria wins major insurer backing for MDMA-assisted therapy

Australia’s biggest health insurer is backing the use of MDMA-based therapy to treat post-traumatic stress disorder in a landmark deal signed with a WA-based biotech.

Cheyanne Enciso

Orthocell chair John Van Der Wielen and chief Paul Anderson at its HQ in Murdoch.

BiotechCommentsPremiumOrthocell’s easy cell into US as it secures distributors

Orthocell says it has moved at ‘warp speed’ to secure US distributors for its nerve repair device, marking another milestone in its commercialisation push into the world’s biggest healthcare market.

Cheyanne Enciso

Telehealth startup BlinkLab hopes to commercialise a smartphone app to help diagnose autism.

BiotechCommentsPremiumBlinkLab raises $7.7m to bankroll smartphone autism test

WA diagnostics startup BlinkLab has raised nearly $8 million to bankroll a clinical trial for its smartphone autism test ahead of a US Food And Drug Administration submission.

Cheyanne Enciso

Orthocell CEO Paul Anderson.

BiotechCommentsPremiumOrthocell adds Canada to string of approvals for Remplir

Orthocell has added Canada to its string of regulatory approvals for its flagship nerve repair product.

Cheyanne Enciso

Orthocell managing director Paul Anderson.

BiotechCommentsPremiumOrthocell shares soar on latest tick for new market entry

WA biotech Orthocell has received the green light to start selling its nerve repair product into the Thai market, worth $131 million.

Cheyanne Enciso

Orthocell boss Paul Anderson holding its Striate+ product.

BiotechPremiumOrthocell posts strong revenue growth following US approval

WA regenerative medicine company Orthocell has posted a near-40 per cent jump in fourth quarter revenue just days after it won a major regulatory clearance in the US.

Cheyanne Enciso

An unhealthy tariff.

BiotechCommentsTrump’s drug hit hint deals fresh blow to Australia

US President Donald Trump has signalled a tariff on imported pharmaceuticals, a policy that is expected to directly hit Australia’s second-largest export to the US.

Jackson Hewett

PYC Therapeutics chief Rohan Hockings at its facility in Nedlands.

BiotechCommentsPremiumPYC Therapeutics facing $13m hole in $146m equity raising

PYC Therapeutics is facing a $13 million hole as one of its underwriters struggle to fill its share of a shortfall from the biotech’s $146m equity raising.

Cheyanne Enciso

Orthocell boss Paul Anderson at its manufacturing facility in Murdoch.

BiotechCommentsPremiumWA’s Orthocell gets green light for $109m Brazilian market

Orthocell has approval to start selling its dental bone repair product into the $US65 million ($109m) Brazilian market.

Cheyanne Enciso

Spearheading calls for the WA Government to match the existing R&D tax incentive is BlinkLab boss Brian Leedman.

The West Australian exclusive
The West Australian exclusive
BiotechCommentsPremium
The West Australian exclusive
‘Shift the dial’: WA biotechs call for R&D top-up scheme

A group of WA biotechs have urged the State Government to match the existing Federal research and development tax incentive in a move they are certain will attract and retain talent.

Cheyanne Enciso

Orthocell CEO Paul Anderson.

updated
updated
BiotechCommentsPremium
updated
‘No need’: Orthocell won’t move production to avoid tariffs

WA biotech Orthocell says there’s no need to shift production to the US to dodge Donald Trump’s tariffs as it wins clearance from the Food and Drug Administration to start selling its nerve repair product.

Cheyanne Enciso

Neurotech boss Anthony Filippis.

BiotechCommentsPremium‘Powerful validation’: Neurotech secures backing in Europe

WA biotech Neurotech has secured the backing of the European Commission for its oral cannabinoid drug therapy aimed at treating Rett syndrome, a rare genetic disorder affecting the way the brain develops.

Cheyanne Enciso

Argenica Therapeutics chief executive Liz Dallimore said the incidence of stroke continued to rise in China, particularly in regional areas. 

BiotechCommentsPremiumWA’s world-first stroke drug gaining attention in China

The biotech says its potentially life-saving drug is drawing increasing interest from major pharmaceutical companies in China, where stroke is now the leading cause of death.

Cheyanne Enciso

PYC Therapeutics chief Rohan Hockings at its facility in Nedlands.

BiotechCommentsPremiumWA biotech PYC Therapeutics rattles tin for $146m

WA biotech PYC Therapeutics is tapping shareholders for up to $146 million to fund the development of its four drug candidates.

Cheyanne Enciso

CSL is Australia’s third-biggest company by market capitalisation at $130 billion.

BiotechCommentsLow vaccination rates in the US dent CSL first-half sales

Low immunisation rates in the US have dented first-half sales for CSL’s flu vaccine business, but the biotech giant says it’s on track to deliver double-digit earnings growth this year.

Cheyanne Enciso

PYC Therapeutics chief Rohan Hockings at its facility in Nedlands.

BiotechCommentsPremiumPYC Therapeutics’ kidney drug approved for human trials

Alan Tribe-chaired PYC Therapeutics has received regulatory approval to commence human trials for its drug aimed at addressing polycystic kidney disease.

Cheyanne Enciso

Telehealth startup BlinkLab hopes to commercialise a smartphone app to help diagnose autism.

BiotechCommentsPremiumBlinkLab gets first US trial site for smartphone autism test

WA telehealth startup BlinkLab has secured its first clinical trial site in the US as it works towards a Food and Drug Administration approval.

Cheyanne Enciso